RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

被引：0
|
作者：
Garcia-Manero, G. [1 ]
Fenaux, P. [2 ]
Al-Kali, A. [3 ]
Baer, M. R. [4 ]
Sekeres, M. [5 ]
Roboz, G. [6 ]
Gaidano, G. [7 ]
Scott, B. [8 ]
Greenberg, P. [9 ]
Platzbecker, U. [10 ]
Steensma, D. P. [11 ]
Kambhampati, S. [12 ]
Kreuzer, K. A. [13 ]
Godley, L. [14 ]
Collins, R. [15 ]
Atallah, E. [16 ,17 ]
Azarnia, N. [18 ]
Petrone, M. E. [19 ]
Snyder, B. R. [20 ]
Maniar, M. [21 ]
Silverman, L. R. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Hosp St Louis, Serv Hematol Seniors, Paris, France
[3] Mayo Clin, Dept Hematol, Rochester, MN USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[6] Weill Cornell Med Coll, Leukemia Serv, New York, NY USA
[7] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Novara, Italy
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[9] Stanford Med Sch, Dept Med Hematol, Stanford, CA USA
[10] Univ Klinikum Dresden, Med Klin & Poliklin 1, Dresden, Germany
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[12] Univ Kansas, Med Ctr, Dept Internal Med, Westwood, KS USA
[13] Univ Klinikum Koln, Dept Internal Med, Cologne, Germany
[14] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[15] Univ Texas Dallas, Dept Internal Med, Dallas, TX 75230 USA
[16] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[17] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[18] Onconova Therapeut Inc, Dept Biometr, Newtown, PA USA
[19] Onconova Therapeut Inc, Dept Pharmacovigilance & Med & Sci Commun, Newtown, PA USA
[20] Onconova Therapeut Inc, Dept Med & Sci Commun, Newtown, PA USA
[21] Onconova Therapeut Inc, Prod Dev Dept, Newtown, PA USA
[22] Icahn Sch Med Mt Sinai, Dept Leukemia, New York, NY 10029 USA
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30113-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
    Brunner, A.
    Porkka, K.
    Knapper, S.
    Traer, E.
    Scholl, S.
    Garcia-Manero, G.
    Vey, N.
    Wermke, M.
    Janssen, J.
    Narayan, R.
    Loo, S.
    Tovar, N.
    Kontro, M.
    Naidu, P.
    Pelletier, M.
    Steensma, D.
    Lewandowski, A.
    Zhang, N.
    Mohammed, A.
    Borate, U.
    Wei, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
  • [42] Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo plus Hypomethylating Agent (HMA)
    Zeidan, Amer M.
    Fenaux, Pierre
    Han, Xia
    James, David A.
    Malek, Kamel
    Ramos, Pedro Marques
    Miyazaki, Yasushi
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [43] A randomized study of two dose levels of intravenous (IV) clofarabibe (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS)
    Jabbour, E.
    Kantarjian, H.
    Garcia-Manero, G.
    Kashani, F. Ravandi
    Borthakur, G.
    Estrov, Z.
    Gandhi, V.
    Byrd, A.
    Kwari, M.
    Faderi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Silverman, Lewis R.
    Scott, Bart L.
    Greenberg, Peter
    Platzbecker, Uwe
    Steensma, David P.
    Kreuzer, Karl A.
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab L.
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROMA PHASE II, OPEN-LABEL STUDY.
    Laille, E.
    Xiao, Z.
    Du, X.
    Dong, Q.
    Songer, S.
    Beach, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81
  • [46] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1
    Zeidan, Amer M.
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Malek, Kamel
    Niolat, Julie
    Kiertsman, Flavia
    Fenaux, Pierre
    BLOOD, 2019, 134
  • [47] Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS
    Cherait, Amina
    Braun, Thorsten
    Bouabdallah, Krimo
    Caillot, Denis
    Guerci, Agnes
    Raffoux, Emmanuel
    Marolleau, Jean Pierre
    Pautas, Cecile
    Banos, Anne
    Himberlin, Chantal
    Taksin, Anne Laure
    Pigneux, Arnaud
    Thomas, Xavier
    Vey, Norbert
    Chevret, Sylvie
    Dombret, Herve
    Chermat, Fatiha
    Ades, Lionel
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2020, 136
  • [48] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai Alexandrovich
    Giri, Smith
    Stahl, Maximilian
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Petrone, Michael E.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2018, 132
  • [50] Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database
    Bewersdof, Jan Philippe
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Logothetis, Constantine
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
12345